Cg Oncology Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $6.2M+446.8% YoYTTM through 30 Jun 2026
Net Income -$224.4MTTM through 30 Jun 2026
Free Cash Flow -$179.3MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | -173.5% |
| Operating Margin | -6,130.1% |
| Net Margin | -3,602.7% |
Returns
-20.8%ROE
-20.7%ROA
Balance Sheet Health
Debt / Equity0.01x
Current Ratio22.22x
Net Debt-$1.1Bnet cash position
Cash & Equivalents$19.6M
Quality Metrics
Altman Z-Score72.81
Piotroski F-Score2 / 9
FCF Margin-2,879.6%
Earnings-Beat Rate25.0%
Multi-Year Trend
RevenueFY2025: $4M
Diluted EPS-$2.69TTMFY2025: $-2.08
Dividend
No dividend
Capital Allocation
Capex Intensity14.1%
Segment Performance
No segment data available.
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.